WO2008078729A1 - 溶出性改善方法 - Google Patents

溶出性改善方法 Download PDF

Info

Publication number
WO2008078729A1
WO2008078729A1 PCT/JP2007/074784 JP2007074784W WO2008078729A1 WO 2008078729 A1 WO2008078729 A1 WO 2008078729A1 JP 2007074784 W JP2007074784 W JP 2007074784W WO 2008078729 A1 WO2008078729 A1 WO 2008078729A1
Authority
WO
WIPO (PCT)
Prior art keywords
dissolution property
improving dissolution
azelnidipine
olmesartan medoxomil
improving
Prior art date
Application number
PCT/JP2007/074784
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Ikumasa Ohno
Ryoichi Hayakawa
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2008551107A priority Critical patent/JP5241512B2/ja
Publication of WO2008078729A1 publication Critical patent/WO2008078729A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2007/074784 2006-12-26 2007-12-25 溶出性改善方法 WO2008078729A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551107A JP5241512B2 (ja) 2006-12-26 2007-12-25 溶出性改善方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006349474 2006-12-26
JP2006-349474 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078729A1 true WO2008078729A1 (ja) 2008-07-03

Family

ID=39562518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074784 WO2008078729A1 (ja) 2006-12-26 2007-12-25 溶出性改善方法

Country Status (4)

Country Link
JP (1) JP5241512B2 (ko)
KR (1) KR20090094285A (ko)
TW (1) TWI488658B (ko)
WO (1) WO2008078729A1 (ko)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
JP2011225537A (ja) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd 固形製剤の製造方法
JP2014224099A (ja) * 2013-04-15 2014-12-04 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
JP2015511635A (ja) * 2012-03-30 2015-04-20 デウン ファーマシューティカル カンパニー リミテッド オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
JP2006298764A (ja) * 2005-04-15 2006-11-02 Sankyo Co Ltd 高血圧症治療に有用な複合体
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1100469T3 (da) * 1998-07-28 2005-04-18 Takeda Pharmaceutical Hurtigt henfaldende fast præparat
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
JP5148296B2 (ja) * 2005-06-27 2013-02-20 第一三共株式会社 アンジオテンシンｉｉ受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
JP2006298764A (ja) * 2005-04-15 2006-11-02 Sankyo Co Ltd 高血圧症治療に有用な複合体
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUMOTO M.: "Yakuzaigaku Manual", vol. 1ST ED., 1989, NANZANDO CO., LTD., HAKKO, pages: 114 *
OKANO T.: "Shin.Yakuzaigaku Soron", vol. 3RD ED., 1987, NANOKODO CO., LTD., HAKKO, pages: 134 - 145 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
JPWO2010107081A1 (ja) * 2009-03-19 2012-09-20 第一三共株式会社 包装により安定保存された固形製剤
JP6081058B2 (ja) * 2009-03-19 2017-02-15 第一三共株式会社 包装により安定保存された固形製剤
JP2011225537A (ja) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd 固形製剤の製造方法
JP2015511635A (ja) * 2012-03-30 2015-04-20 デウン ファーマシューティカル カンパニー リミテッド オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
JP2014224099A (ja) * 2013-04-15 2014-12-04 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物

Also Published As

Publication number Publication date
KR20090094285A (ko) 2009-09-04
TWI488658B (zh) 2015-06-21
TW200835525A (en) 2008-09-01
JP5241512B2 (ja) 2013-07-17
JPWO2008078729A1 (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
AU2009240389A8 (en) Nanoemulsions for treating fungal, yeast and mold infections
MX285041B (es) Composiciones de combustible que contienen farnesano y derivados de farnesano y metodo de preparacion y uso de estas.
WO2008005705A3 (en) Metal-containing formulations and methods of use
HK1127282A1 (en) Solid dosage form of olmesartan medoxomil and amlodipine
PL2044076T3 (pl) Sposób wytwarzania asenapiny i związki pośrednie do stosowania w tym sposobie
WO2008027600A3 (en) Imatinib compositions
IL207792A0 (en) Methods, dosage forms, and kits for administering ziprasidone without food
EP1993322A4 (en) ULTRASOUND SENSOR, AND METHOD OF MANUFACTURING SAME
GB0611443D0 (en) Improvements in, or relating to, particle cassettes
WO2008078726A1 (ja) 固形製剤
HK1093288A2 (en) Fibranchor, manufacture method and application method
WO2010069335A3 (en) Diagnosis of endometritis
WO2008078729A1 (ja) 溶出性改善方法
WO2008021135A8 (en) Syneretic composition, associated method and article
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
GB2435262B (en) Method, composition and articles
WO2007098924A3 (de) Zusammensetzung umfassend ein mittel zum stabilisieren von wirkstoffen im trinkwasser und eine brausemischung, verfahren zu deren herstellung und deren verwendung
WO2009113091A3 (en) Pharmaceutical compositions comprising valsartan
EP2048134A4 (en) MEPTAZINOL DERIVATIVES WITH TWO LIGANDS AND / OR THEIR SALTS, PROCESS FOR PREPARING THEM AND APPLICATIONS THEREOF
WO2008078727A1 (ja) 溶出性の改善された医薬組成物
WO2008073317A3 (en) Cytarabine for treatment of glioma
IL194689A0 (en) Agent, composition and method
BRPI0818783A2 (pt) Método de preparação de (6r)-3-hexil-4-hidróxi-6-undecil-5,6-diidropirano-2-ona, e intermediário empregado no método
WO2008074461A3 (de) Fluoreszenz-nanopartikel
EP2042531A4 (en) COPOLYMER SEQUENCE, COMPOSITION FOR RESIN MODIFICATION AND MODIFIED RESIN COMPOSITION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860013

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551107

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097012652

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860013

Country of ref document: EP

Kind code of ref document: A1